Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (31-40 of 168) with videos related to

Pageof 17
Sort By:
European Journal of Clinical Pharmacology|September 9, 2020
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysisMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
JAMA Internal Medicine|March 1, 2021
Fluoroquinolones and Aortic DiseaseMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
Journal of Global Antimicrobial Resistance|August 22, 2024
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysisMilo Gatti, Pier Giorgio Cojutti, Federico Pea
The Lancet. Infectious Diseases|December 27, 2019
Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteriaMilo Gatti, Maddalena Giannella, Luigia Scudeller, et al.
Acta Diabetologica|April 3, 2019
FreeStyle Libre flash glucose monitoring system in pregnant woman with type 1 diabetes: a focus on accuracyMilo Gatti, Anna Maria Letizia Amato, Daniela Bruttomesso
Antibiotics (Basel, Switzerland)|February 26, 2025
Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric PatientsDésirée Caselli, Maurizio Aricò, Elio Castagnola, et al.
International Journal of Antimicrobial Agents|April 21, 2024
Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations?Milo Gatti, Giulio Virgili, Pierluigi Viale, et al.
Drug Design, Development and Therapy|August 11, 2021
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical NeedsMilo Gatti, Massimo Andreoni, Federico Pea, et al.
Drug Safety|August 5, 2020
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological BasisMilo Gatti, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
European Journal of Internal Medicine|January 28, 2020
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella reviewMilo Gatti, Matteo Bianchin, Emanuel Raschi, et al.
Pageof 17

Showing results (31-40 of 168) with videos related to

Sort By:
Pageof 17
European Journal of Clinical Pharmacology|September 9, 2020
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysisMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
JAMA Internal Medicine|March 1, 2021
Fluoroquinolones and Aortic DiseaseMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
Journal of Global Antimicrobial Resistance|August 22, 2024
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysisMilo Gatti, Pier Giorgio Cojutti, Federico Pea
The Lancet. Infectious Diseases|December 27, 2019
Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteriaMilo Gatti, Maddalena Giannella, Luigia Scudeller, et al.
Acta Diabetologica|April 3, 2019
FreeStyle Libre flash glucose monitoring system in pregnant woman with type 1 diabetes: a focus on accuracyMilo Gatti, Anna Maria Letizia Amato, Daniela Bruttomesso
Antibiotics (Basel, Switzerland)|February 26, 2025
Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric PatientsDésirée Caselli, Maurizio Aricò, Elio Castagnola, et al.
International Journal of Antimicrobial Agents|April 21, 2024
Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations?Milo Gatti, Giulio Virgili, Pierluigi Viale, et al.
Drug Design, Development and Therapy|August 11, 2021
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical NeedsMilo Gatti, Massimo Andreoni, Federico Pea, et al.
Drug Safety|August 5, 2020
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological BasisMilo Gatti, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
European Journal of Internal Medicine|January 28, 2020
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella reviewMilo Gatti, Matteo Bianchin, Emanuel Raschi, et al.
Pageof 17